Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
PBYI Puma Biotechnology, Inc. weekly Stock Chart
PBYI [NASD]
Puma Biotechnology, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.47 Insider Own11.30% Shs Outstand37.69M Perf Week-16.97%
Market Cap297.00M Forward P/E- EPS next Y-1.58 Insider Trans-0.51% Shs Float34.62M Perf Month10.52%
Income-95.10M PEG- EPS next Q-0.50 Inst Own97.00% Short Float19.13% Perf Quarter-27.31%
Sales280.40M P/S1.06 EPS this Y61.90% Inst Trans6.32% Short Ratio3.88 Perf Half Y-43.51%
Book/sh0.44 P/B17.91 EPS next Y24.40% ROA-35.80% Target Price11.71 Perf Year-66.79%
Cash/sh2.93 P/C2.69 EPS next 5Y- ROE-325.90% 52W Range6.26 - 43.90 Perf YTD-61.28%
Dividend- P/FCF- EPS past 5Y-9.50% ROI-55.70% 52W High-82.05% Beta1.67
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin86.80% 52W Low25.88% ATR0.83
Employees272 Current Ratio1.70 Sales Q/Q-9.90% Oper. Margin-29.40% RSI (14)45.24 Volatility14.45% 10.40%
OptionableYes Debt/Eq5.48 EPS Q/Q-16.30% Profit Margin-33.90% Rel Volume1.40 Prev Close7.44
ShortableYes LT Debt/Eq5.48 EarningsNov 06 AMC Payout- Avg Volume1.71M Price7.88
Recom3.30 SMA20-9.98% SMA50-4.95% SMA200-54.86% Volume2,389,115 Change5.91%
Oct-08-19Downgrade Goldman Neutral → Sell $24 → $8
May-10-19Downgrade Citigroup Buy → Neutral $24
May-10-19Downgrade Cantor Fitzgerald Overweight → Neutral $57 → $20
Jan-17-19Initiated Leerink Partners Mkt Perform $21
Jan-03-19Downgrade Guggenheim Buy → Neutral
Nov-19-18Upgrade Goldman Sell → Neutral
Nov-02-18Downgrade JP Morgan Neutral → Underweight
Nov-02-18Downgrade BofA/Merrill Buy → Underperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $75
Sep-17-18Initiated Goldman Sell $42
May-11-18Reiterated Stifel Buy $95 → $87
Nov-10-17Reiterated RBC Capital Mkts Sector Perform $92 → $108
Nov-10-17Reiterated Citigroup Buy $156 → $164
Oct-02-17Reiterated Stifel Buy $110 → $130
Sep-11-17Reiterated Credit Suisse Outperform $118 → $136
Jul-10-17Resumed Leerink Partners Outperform $115
Jun-06-17Reiterated RBC Capital Mkts Sector Perform $60 → $88
May-25-17Reiterated RBC Capital Mkts Sector Perform $40 → $60
Mar-02-17Reiterated RBC Capital Mkts Sector Perform $48 → $17
Sep-22-16Reiterated Credit Suisse Outperform $54 → $111
Dec-06-19 11:31AM  Why Is Puma Biotech (PBYI) Down 1% Since Last Earnings Report? Zacks +5.91%
08:18AM  Those Who Purchased Puma Biotechnology (NASDAQ:PBYI) Shares Five Years Ago Have A 96% Loss To Show For It Simply Wall St.
Dec-03-19 08:59AM  Puma Biotech Expands Pierre Fabre License to Add Countries Zacks -12.86%
07:59AM  The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial Benzinga
Dec-02-19 04:30PM  Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Business Wire +13.07%
11:51AM  CORRECTING and REPLACING Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries Business Wire
Nov-12-19 08:57AM  Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options Zacks
05:40AM  Edited Transcript of PBYI earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-07-19 10:46AM  Puma (PBYI) Q3 Earnings Beat, Nerlynx Sales Weak, Stock Down Zacks +5.40%
Nov-06-19 05:55PM  Puma Biotech (PBYI) Reports Q3 Loss, Lags Revenue Estimates Zacks
04:07PM  Puma Biotechnology Reports Third Quarter 2019 Financial Results Business Wire
08:21AM  The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings Benzinga
Nov-05-19 04:15PM  Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Business Wire
Nov-04-19 04:20PM  Puma Biotechnology to Present at the Credit Suisse Healthcare Conference Business Wire
Oct-31-19 02:06PM  Here is What Hedge Funds Think About Puma Biotechnology Inc (PBYI) Insider Monkey
Oct-30-19 10:33AM  Earnings Preview: Puma Biotech (PBYI) Q3 Earnings Expected to Decline Zacks
Oct-23-19 04:15PM  Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Business Wire
Oct-10-19 11:25AM  How Much Did Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pocket Last Year? Simply Wall St. -5.23%
Oct-08-19 11:08AM  Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks Benzinga -21.95%
Oct-07-19 02:09AM  Edited Transcript of PBYI earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Oct-04-19 11:33AM  Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx Zacks
Oct-03-19 05:00PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
07:34AM  The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo Benzinga
Oct-02-19 04:15PM  FDA Approves Labeling Supplement for Puma Biotechnologys NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
Sep-25-19 04:15PM  Puma Biotechnology to Present at Cantor Global Healthcare Conference Business Wire
Sep-16-19 10:03AM  Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't? Zacks
Sep-13-19 05:27PM  Roche's New Perjeta Combo Meets Goal in Breast Cancer Study Zacks
Sep-12-19 10:13AM  Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance Zacks
Sep-11-19 08:05AM  Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer Business Wire
Sep-10-19 11:41AM  Puma Biotechnology (NASDAQ:PBYI) Has Debt But No Earnings; Should You Worry? Simply Wall St. +15.22%
Sep-07-19 09:30AM  Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report? Zacks
Sep-05-19 05:05PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire +5.18%
Sep-04-19 04:10PM  Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer Business Wire
09:53AM  Puma's Breast Cancer Drug Accorded Orphan Drug Designation For Brain Metastases Benzinga
07:08AM  The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books Benzinga
Sep-03-19 05:30PM  Puma Biotech stock surges on FDA cancer drug designation MarketWatch
04:25PM  Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference Business Wire
04:21PM  FDA Grants Orphan Drug Designation to Puma Biotechnologys NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases Business Wire
Aug-12-19 02:57AM  Puma Biotechnology Inc (PBYI) Q2 2019 Earnings Call Transcript Motley Fool
Aug-09-19 10:31AM  Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up Zacks +21.17%
Aug-08-19 04:05PM  Puma Biotechnology Reports Second Quarter 2019 Financial Results Business Wire
12:18PM  Should You Be Worried About Insider Transactions At Puma Biotechnology, Inc. (NASDAQ:PBYI)? Simply Wall St.
Aug-07-19 08:03PM  Here's Why Puma Biotechnology Fell 24.1% in July Motley Fool
Aug-06-19 05:15PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
12:00PM  ArQule (ARQL) to Post Q2 Earnings: What's in the Cards? Zacks
Aug-01-19 10:32AM  Puma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-25-19 05:05PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jul-24-19 04:15PM  Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Business Wire
Jul-16-19 04:34PM  Puma Biotechnologys Licensing Partner Knight Therapeutics Receives Regulatory Approval from Health Canada to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of Hormone Receptor Positive, HER2-Positive Early Stage Breast Cancer Business Wire
04:30PM  Knight Therapeutics Announces Health Canada Has Approved NERLYNX ® for Early-Stage Breast Cancer GlobeNewswire
Jul-05-19 08:45AM  Implied Volatility Surging for Puma Biotech (PBYI) Stock Options Zacks
Jul-03-19 12:10PM  Puma Biotechnology Presents Interim Results from the Biliary Tract Cohort of its Phase II SUMMIT Basket Trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019 Business Wire
Jul-02-19 05:09PM  Puma Biotech Submits sNDA for Breast Cancer Drug Nerlynx Zacks
Jul-01-19 08:00AM  Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to Treat HER2-Positive Metastatic Breast Cancer Business Wire
Jun-30-19 10:17AM  Wall Street Has Given Up on These 3 Stocks, and That's a Huge Mistake Motley Fool
Jun-24-19 09:52AM  One Thing To Remember About The Puma Biotechnology, Inc. (NASDAQ:PBYI) Share Price Simply Wall St.
09:50AM  Does Market Volatility Impact Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Share Price? Simply Wall St.
Jun-14-19 01:08PM  Did You Manage To Avoid Puma Biotechnology's (NASDAQ:PBYI) Devastating 77% Share Price Drop? Simply Wall St. -5.32%
Jun-12-19 10:56AM  Edited Transcript of PBYI earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-08-19 09:30AM  Puma Biotech (PBYI) Down 53.9% Since Last Earnings Report: Can It Rebound? Zacks
Jun-05-19 01:54PM  Here's Why Puma Biotechnology Tumbled 53.9% in May Motley Fool
07:00AM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Jun-04-19 11:10AM  Puma Biotechnology Presents Results from Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting Business Wire
Jun-03-19 08:32PM  CORRECTING and REPLACING GRAPHIC Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting Business Wire
Jun-02-19 09:00AM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting Business Wire
May-29-19 04:15PM  Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference Business Wire
May-18-19 12:00PM  Investors Are Right to Worry About Puma Biotechnology Motley Fool
May-14-19 07:30AM  Jim Cramer Gives His Opinion On Becton Dickinson, Fox, Puma Biotech And More Benzinga
May-10-19 04:46PM  Biotech Hammered On 'Shockingly Poor' Report For Breast Cancer Drug Investor's Business Daily -38.64%
02:38PM  Here's Why Puma Biotechnology Fell as Much as 40.7% Today Motley Fool
10:53AM  Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales TheStreet.com
10:17AM  Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report Benzinga
10:00AM  Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints Zacks
07:24AM  Puma Biotechnology Inc (PBYI) Q1 2019 Earnings Call Transcript Motley Fool
May-09-19 07:25PM  Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates Zacks
06:24PM  Puma Biotech: 1Q Earnings Snapshot Associated Press
05:40PM  Puma Bio down 33% as more patients forgoing treatment with its cancer drug MarketWatch
04:10PM  Puma Biotechnology Reports First Quarter 2019 Financial Results Business Wire
12:17PM  Here's Why Puma Biotechnology Fell 17.2% in April Motley Fool
May-08-19 04:25PM  Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019 Business Wire
May-05-19 05:53PM  Did Hedge Funds Drop The Ball On Puma Biotechnology Inc (PBYI)? Insider Monkey
May-03-19 04:20PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
May-02-19 10:33AM  Analysts Estimate Puma Biotech (PBYI) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-25-19 04:20PM  Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Business Wire
Apr-18-19 03:01PM  Should You Worry About Puma Biotechnology, Inc.'s (NASDAQ:PBYI) CEO Pay? Simply Wall St.
Apr-09-19 07:16PM  Here's Why Puma Biotechnology Rose 39.5% in March Motley Fool
05:05PM  Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Business Wire
Apr-05-19 09:29AM  Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study Zacks
Apr-04-19 08:30AM  Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations Business Wire
Apr-02-19 10:45AM  Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down Zacks
Apr-01-19 05:13PM  Here's Why Puma Biotechnology Tumbled on Monday Motley Fool -8.12%
02:36PM  Options Volume Spikes on Sinking Drug Stock Schaeffer's Investment Research
09:25AM  The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage Zacks
08:00AM  Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe Business Wire
Mar-30-19 09:30AM  Why Is Puma Biotech (PBYI) Up 39.5% Since Last Earnings Report? Zacks
Mar-28-19 08:30AM  Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 Business Wire
Mar-19-19 05:53PM  Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia Zacks -5.26%
Mar-18-19 04:31PM  Why Edwards Lifesciences, Village Farms International, and Puma Biotechnology Jumped Today Motley Fool +8.17%
03:45PM  Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting Business Wire
08:45AM  Puma Biotechnologys Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRYCE RICHARD PAULSEE REMARKSDec 02Sale10.348385836,455Dec 03 08:53 PM
AUERBACH ALAN HPRESIDENT AND CEODec 02Sale10.334554,7004,187,047Dec 03 04:51 PM
BRYCE RICHARD PAULSEE REMARKSNov 04Sale7.388864936,538Nov 05 04:34 PM
AUERBACH ALAN HPRESIDENT AND CEONov 04Sale7.404783,5374,187,502Nov 05 04:31 PM
BRYCE RICHARD PAULSEE REMARKSOct 02Sale10.059191536,626Oct 03 04:35 PM
AUERBACH ALAN HPRESIDENT AND CEOOct 02Sale9.975045,0274,187,980Oct 03 04:32 PM
HUNT DOUGLAS MSee RemarksSep 12Sale11.421,71119,54012,689Sep 25 04:32 PM
AUERBACH ALAN HPRESIDENT AND CEOSep 04Sale10.145245,3134,188,484Sep 06 04:38 PM
BRYCE RICHARD PAULSEE REMARKSSep 04Sale10.119596036,717Sep 05 04:51 PM
AUERBACH ALAN HPRESIDENT AND CEOAug 02Sale9.035174,6684,189,008Aug 05 06:24 PM
BRYCE RICHARD PAULSEE REMARKSAug 02Sale9.009484636,812Aug 05 06:20 PM
Lo StevenChief Commercial OfficerJul 22Sale10.041,85218,60019,557Jul 24 04:38 PM
BRYCE RICHARD PAULSEE REMARKSJul 22Sale10.101,84118,58936,906Jul 24 04:36 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 22Sale9.9812,715126,8464,189,525Jul 24 04:33 PM
AUERBACH ALAN HPRESIDENT AND CEOJul 02Sale12.784956,3264,202,240Jul 03 06:28 PM
BRYCE RICHARD PAULSEE REMARKSJul 02Sale12.78891,13738,747Jul 03 06:05 PM
BRYCE RICHARD PAULSEE REMARKSJun 03Sale15.07881,32638,836Jun 05 08:04 PM
AUERBACH ALAN HPRESIDENT AND CEOJun 03Sale15.184837,3324,202,735Jun 05 05:12 PM
BRYCE RICHARD PAULSEE REMARKSMay 02Sale32.38852,75238,924May 06 04:39 PM
AUERBACH ALAN HPRESIDENT AND CEOMay 02Sale32.3847715,4454,203,218May 06 04:37 PM
BRYCE RICHARD PAULSEE REMARKSApr 02Sale35.78883,14939,009Apr 03 05:00 PM
AUERBACH ALAN HPRESIDENT AND CEOApr 02Sale35.7949117,5734,203,695Apr 03 04:58 PM
BRYCE RICHARD PAULSEE REMARKSMar 04Sale38.66883,40239,097Mar 22 04:53 PM
AUERBACH ALAN HPRESIDENT AND CEOMar 04Sale38.6249619,1564,204,186Mar 22 04:51 PM
EYLER CHARLES RSEE REMARKSFeb 04Sale27.64872,40531,957Feb 06 04:38 PM
BRYCE RICHARD PAULSEE REMARKSFeb 04Sale27.77892,47229,285Feb 06 04:34 PM
AUERBACH ALAN HPRESIDENT AND CEOFeb 04Sale27.803459,5914,165,467Feb 06 04:30 PM
Lo StevenChief Commercial OfficerJan 22Sale24.912,11452,66421,409Jan 24 04:54 PM
EYLER CHARLES RSEE REMARKSJan 22Sale24.8071317,68232,044Jan 24 04:51 PM
BRYCE RICHARD PAULSEE REMARKSJan 22Sale24.721,95948,42629,374Jan 24 04:47 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 22Sale24.748,825218,3344,165,812Jan 24 04:44 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 03Sale20.674,42491,4444,174,637Jan 04 06:26 PM
EYLER CHARLES RSEE REMARKSJan 03Sale20.671,21025,01132,757Jan 04 05:16 PM
BRYCE RICHARD PAULSEE REMARKSJan 03Sale20.671,21025,01131,333Jan 04 05:08 PM
open in yahoo | open in reuters | open in google